Semaglutide vs Ozempic: Are They the Same Drug?

What Is Semaglutide?

Semaglutide is a GLP-1 receptor agonist — a class of medication that mimics glucagon-like peptide-1, a hormone naturally produced in the gut after eating. GLP-1 signals the pancreas to release insulin, slows gastric emptying (so food stays in the stomach longer), and most importantly for weight management, sends satiety signals to the brain that reduce appetite.

Semaglutide was developed by Novo Nordisk and received its first FDA approval in 2017 for type 2 diabetes management. In 2021, it received a separate FDA approval for chronic weight management under the brand name Wegovy — at a higher weekly dose. The STEP trials for Wegovy showed an average body weight reduction of 14.9% over 68 weeks, making it one of the most effective pharmaceutical weight loss treatments ever approved.

The Three Semaglutide Brands: What Is Different

Brand list prices are approximate and vary by insurance coverage. Compounded pricing varies by provider and pharmacy.

Why Does Novo Nordisk Sell the Same Drug Under Three Names?

This is a common pharmaceutical strategy. FDA drug approvals are indication-specific — each new indication (diabetes vs. obesity vs. oral dosing) requires separate clinical trials and approval. A company that runs those trials receives a distinct product approval with its own patent protection, pricing, and reimbursement negotiations.

The practical result: the exact same molecule costs different amounts depending on what you say you are using it for — and whether your insurance covers that specific indication. Many insurance plans cover Ozempic for diabetes but not Wegovy for weight loss, even though they are the same drug at different doses.

What Is Compounded Semaglutide?

Compounded medications are prepared by licensed compounding pharmacies using pharmaceutical-grade active pharmaceutical ingredients (APIs). Compounding is regulated under federal law and FDA oversight. When a brand-name drug is on the FDA’s drug shortage list, compounding pharmacies are legally permitted to compound that drug — and semaglutide has been on and off the shortage list as demand for Ozempic and Wegovy has far outpaced Novo Nordisk’s production capacity.

Compounded semaglutide from an accredited 503B outsourcing facility uses the same semaglutide API as Ozempic/Wegovy. The significant difference is price: compounded semaglutide typically costs $200–$500/month versus $900–$1,300 for brand-name Wegovy without insurance. That gap is why compounded semaglutide became the primary access point for weight loss treatment for millions of Americans.

Important caveat: FDA regulations around compounding change over time and depend on drug shortage status. Your Affinity provider will advise on current availability.

How Effective Is Semaglutide for Weight Loss?

The STEP 1 trial — 68 weeks of semaglutide 2.4mg weekly — produced a mean weight reduction of 14.9% of body weight. For a 220-pound person, that is approximately 33 pounds. The placebo group lost 2.4%. These are the largest sustained weight loss results ever observed in a pharmaceutical trial at the time.

Results require consistent use and are not permanent. Weight typically returns when medication is stopped, because GLP-1 agonists are treating the underlying hormone signaling, not permanently changing it. This positions semaglutide as a long-term maintenance therapy, not a short course.

Common Questions

This article is written and reviewed by the Affinity Direct clinical team for informational purposes. It does not constitute medical advice. All prescriptions require a provider evaluation. Compounding availability is subject to FDA regulations and may change. Last reviewed: May 2025.